Koshinski Asset Management Inc. Lowers Stock Holdings in Becton, Dickinson and Company $BDX

Koshinski Asset Management Inc. lessened its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.0% during the second quarter, HoldingsChannel reports. The firm owned 6,361 shares of the medical instruments supplier’s stock after selling 63 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $1,096,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC boosted its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Becton, Dickinson and Company by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock worth $744,000 after acquiring an additional 748 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in shares of Becton, Dickinson and Company by 50.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier’s stock worth $18,808,000 after acquiring an additional 27,581 shares during the last quarter. Ritholtz Wealth Management purchased a new stake in Becton, Dickinson and Company in the first quarter valued at approximately $224,000. Finally, Sowell Financial Services LLC acquired a new position in Becton, Dickinson and Company during the first quarter worth approximately $348,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 2.1%

Shares of Becton, Dickinson and Company stock opened at $189.20 on Friday. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a market capitalization of $54.23 billion, a PE ratio of 34.03, a P/E/G ratio of 1.48 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The business has a 50-day moving average of $190.60 and a 200-day moving average of $184.63.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.32 billion during the quarter. As a group, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were issued a $1.04 dividend. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is currently 74.82%.

Analyst Ratings Changes

A number of equities analysts have weighed in on BDX shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Morgan Stanley increased their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Royal Bank Of Canada reissued a “sector perform” rating and set a $211.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday. Argus increased their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Finally, Piper Sandler reiterated a “neutral” rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $205.40.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares of the company’s stock, valued at $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 1,838 shares of company stock worth $348,392. Corporate insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.